Potent inhibitory activities of hydrophobic aci-reductones (2- hydroxytetronic acid analogs) against membrane and human low-density lipoprotein oxidation

Biochemical Pharmacology

Volumn 55, Issue 11, 1998, Pages 1921-1926

  Mak, I Tong ^a   Murphy, Alex ^a   Hopper, Allen ^b   Witiak, Donald ^b   Ziemniak, John ^c   Weglicki, William B ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c OXIS International Inc   (United States)

Author keywords

Anti atherogenic effect; Antioxidant activity; Ascorbic acid derived hydrophobic aci reductones; Copper induced LDL peroxidation

Indexed keywords

2 HYDROXYTETRONIC ACID; 4 CHLOROPHENYL 2 HYDROXYTETRONIC ACID; ALPHA TOCOPHEROL; ASCORBIC ACID; COPPER; FERROUS ION; LOW DENSITY LIPOPROTEIN; TETRONIC ACID DERIVATIVE; TROLOX C; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROGENESIS; CHEMICAL STRUCTURE; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; LIPID PEROXIDATION; LIVER MICROSOME; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTILIPEMIC AGENTS; BIPHENYL COMPOUNDS; DRUG EVALUATION, PRECLINICAL; FURANS; HUMANS; INTRACELLULAR MEMBRANES; LIPID PEROXIDATION; LIPOPROTEINS, LDL; MEMBRANE LIPIDS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0032101084     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00079-3     Document Type: Article

References (24)

1. Halliwell B., Gutteridge J.M.C. Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J. 219:1984;1-14.
2. Kehrer J.P. Free radicals as mediators of tissue injury and disease. Crit Rev Toxicol. 23:1993;21-48.
3. Witiak D.T., Kokrady S.S., Patel S.T., Huzoor Akbar, Feller D.R., Newmann H.A.I. Hypocholesterolemic and antiaggregatory properties of 2-hydroxytetronic acid redox analogues and their relationship to clofibric acid. J Med Chem. 25:1982;90-93.
4. Witiak D.T., Kim S.K., Tehim A.K., Sternitzke K.D., McCreery R.L., Kim S.U., Feller D.R., Romstedt K.J., Kamanna V.S., Newman H.A.I. Synthetic aci-reductones 3,4-dihydroxy-2H-1-benzopyran-2-ones and their cis- and trans-4a,5,6,7,8,8a-hexahydro diastereomers. Antiaggregatory, antilipidemic, and redox properties compared to those of the 4-substituted 2-hydroxytetronic acids . J Med Chem. 31:1988;1437-1445.
5. Steinberg D., Parthasarathy S., Carew T., Khoo J., Witztum J. Beyond cholesterol, modification of low density lipoprotein that increases its atherogenicity. N Engl J Med. 320:1989;915-918.
6. Diaz M.N., Frei B., Vita J.A., Keaney J.F. Antioxidants and atherosclerotic heart disease. N Engl J Med. 337:1997;408-416.
7. Mak I.T., Weglicki W.B. Membrane antiperoxidative activities of D-propranolol, L-propranolol and dimethyl-quaternary propranolol. Pharmacol Res. 25:1990;25-30.
8. Tse S.Y.H., Mak I.T., Dickens B.F. Antioxidative properties of harmane and β-carboline alkaloids. Biochem Pharmacol. 42:1991;459-464.
9. Mak I.T., Kramer J.H., Weglicki W.B. Potentiation of free radical induced peroxidative injury to sarcolemmal membranes by lipid amphiphiles. J Biol Chem. 261:1986;1153-1157.
10. Mak I.T., Weglicki W.B. Antioxidant properties of calcium channel blocking drugs. Methods Enzymol. 234:1994;620-630.
11. Esterbauer H., Gebicki J., Puhl H., Jurgens G. The role of lipid peroxidation and antioxidants in oxidative modifications of LDL. Free Radic Biol Med. 13:1992;341-390.
12. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72:1976;248-254.
13. Wills E.D. Lipid peroxidation formation in microsomes. The role of non-haem iron. Biochem J. 113:1969;325-332.
14. Gutteridge J.M.C., Halliwell B., Treffry A., Harrison P.M., Blake D. Effect of ferritin-containing fractions with different iron loading on lipid peroxidation. Biochem J. 209:1983;557-560.
15. Mak I.T., Weglicki W.B. Characterization of iron-mediated peroxidative injury in hepatic lysosomes. J Clin Invest. 75:1985;58-63.
16. Niki E. Interaction of ascorbate and α-tocopherol. Ann NY Acad Sci. 498:1987;186-199.
17. Mak I.T., Weglicki W.B. Protective effect of β-blocking agents against free radical-mediated sarcolemmal lipid peroxidation. Circ Res. 63:1988;262-266.
18. Mak I.T., Weglicki W.B. Comparative antioxidant activities of propranolol, nifedipine, verapamil and diltiazem against sarcolemmal membrane lipid peroxidation. Circ Res. 66:1990;1449-1452.
19. Oliver M.F., Heady J.A., Morris J.N., Cooper J. A co-operative trial in the primary prevention of ischemic heart disease using clofibrate. Br Heart J. 40:1978;1069-1118.
20. Reddy J.K., Azarnoff D.L., Hignite C.E. Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature. 283:1980;397-398.
21. Kamanna V.S., Newman H.A.I., Patel S.T., Tehim A.K., Witiak D.T., Feller D.R. Serum lipoprotein and apoprotein concentrations in CHTA and clofibrate-treated cholesterol and cholic acid-fed rats. Lipids. 24:1989;25-32.
22. Triozzi P.L., Ailabouni J., Rinehart J.J., Witiak D.T. Aci-reductones enhance interleukin-2-induced lymphocyte cytotoxicity. Int J Immunopharmacol. 15:1993;47-54.
23. Frimer A.A., Marks V., Gilinsky-Sharon P., Aljadeff G., Gottlieb H.E. Reaction of superoxide with aci-reductones. J Org Chem. 60:1995;4510-4520.
24. Tardif J-C, Cote G., Lesperance J., Bourassa M., Lambert J., Doucet S., Bilodeau L., Nattel S., De Guise P. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med. 337:1997;365-372.